Target Selectivity of Dabrafenib (GSK2118436)

Key TargetIC50DescriptionReference
Unaltered EGFR 0.0004 µM Data from PubChem database PMC11199933
Altered EGFR (V774M) 0.69 µM Data from PubChem database PMC11199933
Check the Dabrafenib (GSK2118436) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Cell-free Assays (IC50/Ki) for Dabrafenib (GSK2118436)

Key TargetIC50 (Cell-free)DescriptionReference
Unaltered EGFR 0.0004 µM Data from PubChem database PMC11199933
Altered EGFR (V774M) 0.69 µM Data from PubChem database PMC11199933

Cell-based Assay (IC50) for Dabrafenib (GSK2118436)

Cell TypeIC50 (Cell-based)DescriptionReference
A375 melanoma cells 0.7 ± 0.4 µM XTT cell viability assay, CalcuSyn software Download PDF
RPMI 7951 melanoma cells 0.9 ± 0.5 µM XTT cell viability assay, CalcuSyn software Download PDF
A549 40.17 µM RSV-GFP inhibition measured by fluorescence intensity; Cell viability determined using CyQUANT MTT Cell Proliferation Assay Kit. PMC12720153
ME4686DR ≥ 1µM Cell Titer-Glo Luminescent Cell Viability assay Download PDF
ME4686 4.11nM Cell Titer-Glo Luminescent Cell Viability assay Download PDF

Jump to